A. Rozova

Deferiprone‐induced agranulocytosis: 20 years of clinical observations

J. Palmblad, M. Spino, R. Galanello, 2016, American journal of hematology.

The pharmacokinetic and safety profile of single-dose deferiprone in subjects with sickle cell disease

F. Tricta, D. Soulières, A. Rozova, 2022, Annals of Hematology.

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years

F. Tricta, Y. Kilinç, Mohsen Saleh Elalfy, 2022, Blood advances.

Extended-release tramadol/paracetamol in moderate-to-severe pain: a randomized, placebo-controlled study in patients with acute low back pain

K. Rainsford, A. Rozova, B. Lasko, 2012, Current medical research and opinion.

Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study.

D. Sheehan, H. Croft, A. Rozova, 2009, Psychiatry (Edgmont (Pa. : Township)).

The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.

D. Sheehan, M. Gibertini, A. Rozova, 2009, Psychopharmacology bulletin.

Randomized, Blinded, Placebo‐ and Positive‐Controlled Crossover Study to Determine the Effect of Deferiprone on the QTc Interval in Healthy Subjects

F. Tricta, A. Rozova, M. Allison, 2018, Clinical pharmacology in drug development.

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

M. Spino, F. Tricta, A. El‐Beshlawy, 2019, Blood.